Argenx, a leading immunology company, is set to host a conference call and audio webcast on May 9, 2024, at 2:30 PM CET. During the event, the company will discuss its first quarter financial results and provide an update on its business. The webcast can be accessed through the Investors section of the argenx website. A replay of the webcast will be available for approximately one year after the presentation.
Dial-in numbers have been provided for participants from various countries, with an access code required to join the call. It is recommended to dial in 15 minutes before the scheduled start time to ensure a smooth connection.
Argenx’s focus is on translating immunology breakthroughs into novel antibody-based medicines through its Immunology Innovation Program (IIP). The company has developed and commercialized the first approved neonatal Fc receptor (FcRn) blocker in several countries. Currently, argenx is evaluating efgartigimod in multiple serious autoimmune diseases and progressing experimental medicines within its therapeutic franchises.
For more information about argenx, including its portfolio of medicines and ongoing research, visit the company’s website and follow their social media accounts. For media inquiries, please contact Ben Petok, and for investor relations, contact Alexandra Roy for the US and Lynn Elton for the EU.
